A. Amin

P. Ascierto, P. Ott, M. Hellmann, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer

G. Mayhew, M. Milburn, M. Milla, 2022, Cancer research communications.

9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901.

E. Gelmann, E. Small, W. Stadler, 2004, Urologic oncology.

First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy

N. Tannir, H. Hammers, A. Amin, 2018, Current medical research and opinion.

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).

E. Plimack, M. Voss, P. Sharma, 2014 .

Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC).

R. Figlin, V. Master, M. Debenedette, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ipilimumab in Treatment-naive and Previously Treated Patients with Metastatic Melanoma: Retrospective Analysis of Efficacy and Safety Data from a Phase II Trial

O. Hamid, J. Weber, D. Minor, 2012, Journal of immunotherapy.

Sequential immune monitoring in patients with melanoma and renal cell carcinoma treated with high-dose interleukin-2: immune patterns and correlation with outcome

I. McKillop, D. Foureau, T. Sarantou, 2014, Cancer Immunology, Immunotherapy.

Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series

R. Amaria, H. Tawbi, S. Patel, 2019, Cancer.

Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC).

D. Jäger, P. Ascierto, P. Ott, 2016 .

Effect of prior treatment status on the efficacy and safety of ipilimumab monotherapy in treatment-naive and previously treated patients with advanced melanoma

O. Hamid, J. Weber, D. Minor, 2008 .

Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients

U. Hamann, N. Muhammad, M. U. Rashid, 2012, Familial Cancer.

Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study

E. Plimack, M. Voss, P. Sharma, 2016 .

1052PDNIVOLUMAB (N) (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH SUNITINIB (S) OR PAZOPANIB (P) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC).

E. Plimack, M. Voss, B. Rini, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.

R. Janssen, A. Ribas, G. Daniels, 2018, Journal of Clinical Oncology.

Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy.

J. Patel, A. Amin, K. Mileham, 2021, Thrombosis research.

MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial

D. Jäger, P. Ascierto, P. Sharma, 2017 .

1050OPHASE I STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC).

E. Plimack, M. Voss, B. Rini, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Flexible Sigmoidoscopy Rather than Colonoscopy Is Adequate for the Diagnosis of Ipilimumab-Associated Colitis

M. Kamionek, V. Maddukuri, K. Bossi, 2019, Southern medical journal.

A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM).

F. Hodi, T. Guthrie, A. Salama, 2015 .

Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.

E. Schmidt, R. Janssen, A. Ribas, 2019, Journal of Clinical Oncology.

Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell renal cell carcinoma (mccRCC).

R. Motzer, E. Plimack, M. Voss, 2015 .

Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib.

R. Figlin, V. Master, M. Debenedette, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib.

R. Figlin, J. Holzbeierlein, R. Lance, 2010 .

1105PVEMURAFENIB FOR BRAF V600 MUTATED ADVANCED MELANOMA: RESULTS OF TREATMENT BEYOND PROGRESSION.

Y. S. Kim, Su Jin Lee, J. Utikal, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients

U. Hamann, J. L. Bermejo, N. Muhammad, 2016, BMC Cancer.

Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

E. Cohen, A. Algazi, D. Laux, 2018, Annals of Oncology.

Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced renal cell carcinoma (aRCC; CheckMate 214).

B. Rini, M. Grimm, C. Kollmannsberger, 2018 .

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

D. Jäger, P. Ascierto, P. Sharma, 2016, The Lancet. Oncology.

Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan

U. Hamann, N. Muhammad, M. U. Rashid, 2016, Breast Cancer Research and Treatment.

Ipilimumab (IPI) Expanded Access Program (EAP) for Patients (PTS) with Stage III/IV Melanoma: Safety Data by Subgroups

J. Wolchok, F. Hodi, D. Lawrence, 2012 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

R. Figlin, W. Miller, V. Master, 2015, Journal of Immunotherapy for Cancer.

Safety and efficacy of ipilimumab in melanoma patients who received prior immunotherapy on phase III study MDX010-020.

W. Urba, H. Kaufman, D. McDermott, 2013 .

Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.

C. Porta, R. Motzer, T. Powles, 2019, Journal of Clinical Oncology.

Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC).

R. Figlin, V. Master, M. Debenedette, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.